ALL   

The patient presented with a numb chin, more to the right of his face; an MRI did report mandibular nerve opacity, which is non-specific per neuro-rad...

For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.&nbs...

Transplant is not part of the trial but is the standard outside of the trial. A041501 is a phase III trial to evaluate the efficacy of the addition of...

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

The patient was recently diagnosed with pre-B ALL and is on day 10 of CALGB 10403. He is expectedly neutropenic as he received daunorubicin and vincri...

For a pediatric patient with B-ALL who needs elective surgery during maintenance, what are potential treatment options during the month recommended fo...

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

What are the differences in approach to B lymphoid/myeloid and T lymphoid/myeloid MPAL?

What is the role of PD-1 inhibitors after CAR-T infusion, either as maintenance therapy or in the setting of relapsed disease? 

Do you routinely check IgG levels during therapy, if not indicated by a study protocol?

Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...

Based on St. Judes, DFCI, and BFM data, COG has recently decreased the length of therapy for males with B-Cell ALL.  Can this be extrapolated to ...

Late relapse is > 36 months from diagnosis.  

With the new COG leukemia studies, it is difficult to interpret these results in the context of their clinical status and conventional MRD 

Patient's leukemia has both T and Myeloid lineages 

For example, if the patient was on dasatinib before relapse, would you consider other second generation or third generation TKIs?

Does acute leukemia sub-type affect your decision? 

What is your preferred treatment?

The NCCN recommends both regimens. 

Outcomes for these patients are dismal, so looking for any insight on how to optimize outcomes for these patients.

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?